AIM ImmunoTech Inc. Files Form 8-K: Removes Cap on At-the-Market Offering

Key Highlights for Investors

• Significant Amendment to Equity Distribution Agreement: On April 10, 2026, AIM ImmunoTech Inc. (“AIM” or the “Company”) executed Amendment No. 1 to its previously established Equity Distribution Agreement (the “Sales Agreement”) with Maxim Group LLC (“Maxim”).
• Unlimited At-the-Market Offering: The critical change is the removal of the previous dollar limitation on the number of shares that can be issued and sold under the Sales Agreement. Previously, the Company was limited to issuing up to \$3,000,000 of common stock, but now, under the amended agreement, there is no specified cap.
• Ongoing Capital Raising: The Company can now issue and sell, from time to time, an unlimited amount of its authorized but unissued shares of common stock through Maxim as its exclusive sales agent in an at-the-market (“ATM”) public offering.
• Legal and Regulatory Compliance: All shares sold under this arrangement will be made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-286319) and related prospectus supplements, as required under U.S. securities laws. A new prospectus supplement is being filed simultaneously to reflect the increased number of shares available for sale.
• Shareholder Approval and Validity: The legal opinion from Thompson Hine LLP, filed as Exhibit 5.1, confirms that any shares issued under the amended agreement will be duly authorized, validly issued, fully paid, and non-assessable.

Details Shareholders Should Note

• POTENTIAL SHARE DILUTION: With the removal of the cap on the equity distribution, the Company now has the flexibility to raise capital more opportunistically but also introduces the possibility of significant dilution for existing shareholders, depending on the volume and pricing of future share sales.
• Share Price Implications: This amendment is potentially price-sensitive. The increased ability to issue shares could put downward pressure on AIM’s share price if the market anticipates or observes a substantial increase in share supply. Conversely, the increased financial flexibility may be seen positively if the capital is used for value-creating opportunities.
• Exclusive Sales Agent: Maxim Group LLC remains the exclusive sales agent, responsible for soliciting purchases and using commercially reasonable efforts in the sale of AIM’s common stock on the Company’s behalf.
• Legal Disclosures:
  • Amendment No. 1 and the legal opinion are both filed as exhibits to the Form 8-K.
  • The Company is not an emerging growth company as defined under Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Exchange Act of 1934.
  • No written communications, soliciting material, or pre-commencement tender offers are associated with this filing.
• Common Stock Details:
  • Trading Symbol: AIM
  • Exchange: NYSE American
  • Class: Common Stock, par value \$0.001 per share

Further Information

• The amendment to the Equity Distribution Agreement, the legal opinion, and related documents are available as exhibits to the Form 8-K for further review by shareholders.
• All sales will be made under the previously declared effective registration statement and a newly filed prospectus supplement to reflect the amendment.

Conclusion

The removal of the limitation on at-the-market offering capacity is a material event for AIM ImmunoTech Inc. This change provides the Company with enhanced flexibility to raise capital but may lead to increased dilution risk for existing shareholders. Investors should closely monitor share issuance activity and the Company’s use of proceeds, as these could materially impact the Company’s share price and overall shareholder value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a financial advisor before making investment decisions. The author is not responsible for any investment actions taken based on this article.

View AIM ImmunoTech Inc. Historical chart here